Trial Profile
A Multiple-Dose Targeting Study of hu3S193 [monoclonal antibody 3S193] in Patients With Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3S193 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 12 Sep 2005 New trial record.